
SNWV Stock Forecast & Price Target
SNWV Analyst Ratings
Bulls say
SANUWAVE Health demonstrated impressive financial performance in 2024, achieving a 60% year-over-year sales growth, resulting in revenue of $32.6 million driven by both system sales and consumables. The company also significantly improved its adjusted EBITDA margin, increasing by 28 points to 22%, indicating enhanced operational efficiency. Despite a rise in operating expenses to $6.4 million, primarily due to non-cash stock-based compensation and NASDAQ fees, the overall financial metrics suggest a strong and positive outlook for the company's future.
Bears say
The financial analysis indicates a negative outlook for SANUWAVE Health's stock primarily due to decreased applicator usage in the first quarter, which reflects a typical seasonal patient behavior pattern after the resetting of annual insurance deductibles. Additionally, concerns such as margin compression, competitive headwinds, reduced sales representative productivity, and potential manufacturing setbacks pose significant risks to the company's growth and operational efficiency. These factors collectively point to challenges in maintaining sales momentum and profitability, which could adversely affect SANUWAVE Health's financial performance.
This aggregate rating is based on analysts' research of SANUWAVE Health Inc and is not a guaranteed prediction by Public.com or investment advice.
SNWV Analyst Forecast & Price Prediction
Start investing in SNWV
Order type
Buy in
Order amount
Est. shares
0 shares